Loading...

Thursday, January 29, 2009

An Article by David Ristau From The Oxen Group

What is there to play in 2009? That question has been kicked around this year, thus far. Financials are a no go. Tech is ugly. Energy is unpredictable. Autos are bad. Consumer goods, yuck!So, what is an investor looking for something that will grow this year. It is time to introduce education companies into your portfolio. Education companies, such as ITT Educational Services (ESI), Apollo Group (APOL), who owns University of Phoenix, and DeVry Inc. (DV) have recently been seeing success during the economic downturn and appear to be a solid play moving forward this year.The thinking behind the success of these companies is, plainly, if job losses continue to increase, then there are measures that individuals will take to battle the job market's woes. One of those measures would be to increase one's attributes, aka, further their education. That is why these companies will continue to a rise in applications, as jobs continue to decrease.The group of companies are beginning to show the increase in participants through quarterly earnings. Last quarter, DeVry increased their EPS by 0.14 and their revenue by 9%. This quarter the company is estimated to report, on January 27th, a revenue of $364 million, which would be an increase from last quarter of almost 20%. Apollo Group, on January 8, reported an EPS of 1.12, which was an increase from last quarter of .75 EPS and an increase in revenue 17%. The same numbers are true for ITT Educational, as well.So, if there has already been success, then have you missed the moment to get in? No, not at all. These companies are going to continue to grow until the market turns around. Just last week, however, some of the country's most important and largest names in the world announced more layoffs. The end of this movement is not near.Where do the risks in this idea lie? Well, many of these companies need government funding both for their students and themselves. If any of this funding were to decrease, it would considerably hurt these companies ability to be successful. Much of the revenue these companies receive is from governmental grants and funding. That risk, however, appears to be much less after the recent announcements of the Obama stimulus package. One of the proponents of this package is increase in Pell Grant funding by $15.6 million, therefore increasing lending to citizens, while private firms decrease investing.These stocks appear to me to be very attractive securities to own right now. The first stock I would want to get in would be DeVry because of its upcoming earnings that should be better than expected. The other two mentioned are strong plays, although Apollo may be a bit overpriced. Other options include Career Education Company (CECO) and Strayer Education (STRA).Get in before its too late. These stocks are a great reverse play in these hard times.

The Oxen Group

Tuesday, January 27, 2009

Great News For These Three Stocks; CRYP, EPCT, CSUH.OB

CRYP, Cryptologic Limited
CryptoLogic Limited is a leading software developer for the global Internet gaming market.

During the past nine months, Cryptologic's (CRYP) stock price has tumbled from well over the $20 mark to below $5. Factors which influenced the drastic drop in price include, but are not limited to, legislation in the United States that hurt online gambling and the economic slowdown that cut into the company's profits; not to mention the general market conditions that have slashed value throughout the world of securities.

Although the stock dropped below the five dollar level, the company continued to announce new licensing agreements and cost-cutting measures, which made CRYP a great buy, in my opinion.

Since the new year, the company has issued guidance that indicates a return to profitability in 2009 to the tune of $9-$10 million. They have also announced a strategic partnership with Gaming Technology Solutions PLC (GTS), a leading global supplier of platform solutions for online gaming operations, that will give Cryptologic a new channel with which to market its software.

The stock reacted positively to both Press Releases, but it was an upgrade from 'Hold' to 'Buy' by Roth Capital that once again pushed CRYP over the $5 mark. It would not be a surprise, however, to have the chance to buy back in at under $4 with the current market volatility.

Today's market offers no guarantees, but with new and existing licensing agreements and cost-cutting measures in place, CRYP could be a great rebound story as the economy, and the market, recovers.

YourOfficialCreditReport

EPCT, Epicept Corporation

Epicept recently received authorization in Europe to market and distribute its primary drug treatment, Ceplene. Ceplene is a treatment used in the remission maintenance of AML patients and could possibly bring in revenue for the company as early as this year. News of a partnership to market and distribute Ceplene in Europe could come at any time, according to a recent Press Releases by the cmpany.

In addition to Ceplene, the company just issued positive Phase II results for another one of its drug candidates, NP-1. NP-1 is a prescription topical analgesic cream designed to provide effective, long-term relief from the pain of peripheral neuropathies.

In the Press Release the company stated that the Phase IIb trial met its primary endpoints and demonstrated a favorable safety profile compared with Gabapentin.

The news was good for only a four cent rise in price (68 cent close), but more importantly, it adds to the great risk-reward profile for this small company that holds a solid drug pipeline (in my opinion).

Aside from the already approved Ceplene and the positive Phase IIb trial for NP-1, another success story could be Azixa, Epicept's brain cancer treatment that is currently being tested in clinical trials by Myriad. Nearly two years ago, the stock price of EPCT jumped to over $4 on positive results from early stages of these trials. Another update on the Azixa trials is due this year.

Biotechs carry above average risk but they also have the potential to offer above average rewards if you're in the stock early enough. In my opinion, EPCT is one of the better risk-reward biotech stocks out there right now.
ShareBuilder- Welcome page

CSUH.OB, Celsius Holdings

Celsius Holdings, maker of the world's first calorie burning beverage, possibly released the most significant news in the company's history today when CEO Steve Haley announced that the Celsius Green Tea flavors will soon be available in most GNC stores nationwide.

Although Celsius is already available is many national and local outlets, including the Vitamin Shoppe, GNC is the recognized leader in sports nutrition and gives Celsius much needed exposure and credibility.

The move into GNC is an indication, in my opinion, that the Carl DeSantis influence is beginning to pay dividends.

With television and radio ads gearing up along with increased exposure, this could turn out to be a great year for shareholders of CSUH.OB as the Celsius beverage gains a solid, national foothold in the beverage industry.

Critics cite that Celsius has not been well received in other retail outlets, but GNC is a natural fit for the calorie-burning brand as opposed to the convenience stores where the product previously failed to catch on.

The company is still laden with debt, but a Carl DeSantis subsidiary company has refinanced that debt at agreeable terms.

Added exposure came when Katie Holmes was photographed next to an assistant who was carrying Celsius and the photo made the tabloids in both the US and England, accompanied with speculation that the star may be using the drink to lose weight.

All else aside, the GNC news could be the significant boost that this company has needed to propel the business, and hopefully stock price, forward.

Celsius Catches on With Katie Holmes
VFC's 2009 Stock Picks
Comments from Celsius CEO Steve Haley
Comments from Celsius CEO Steve Haley, Part I

Wirefly - T-Mobile G1 with Google Touch Screen Phone + Free FedEx Shipping with a new T-Mobile account

VFC's 2009 Stock Picks, Part III
VFC's 2009 Stock Picks, Part I
VFC's 2009 Stock Picks, Part II

Novadel, NVD
VFC's Bear Market Stock Picks Part I
VFC's Bear Market Picks Part II
VFC's Bear Market Picks Part III
VFC's Bear Market Non Picks Part
VFC's Stock Updates
VFC's Bear Market Picks Part IV; CRYP, CSUH.OB
VFC's Biotech Picks
VFC's Quarterly Updates
INSM Update, IPLEX Back In Action

Wednesday, January 14, 2009

VFC's 2009 Stock Picks, Part III

VFC's 2009 Stock Picks, Part I
VFC's 2009 Stock Picks, Part II

BDSI, BioDelivery Sciences International:
Like Dendreon (DNDN), BioDelivery Sciences is another drug development company with big news due out in 2009. The FDA is expected to rule on BioDelivery's lead drug candidate, Onsalis, by mid year. All indications up to this point are that Onsolis has a good chance of approval.

Onsolis is a treatment for pain in opioid tolerant patients with cancer.

With a current market cap of approximately 58 million, the approval of Onsolis should propel the BDSI stock significantly upward.

The company also recently announced that it has expanded a pre-existing partnership with Meda AB that provided BioDelivery Sciences with a $3 million advance from the $30 million milestone payment the Meda will pay upon Onsolis approval. In return, Meda AB now has exclusive rights to distribute Onsolis in all countries except Taiwan and South Korea.

In addition to Onsolis, BioDelivery Sciences has two additional drug candidates in early stages of development. However, those drugs are too far off to count on now. If you buy BDSI now, it should be for the Onsolis play.

VFC will be accumulating as long as the stock remains in the three dollar range. I'm comfortable with my currents holdings, so I will hold above that level.
ShareBuilder- Welcome page

Two Stocks that are getting hammered now as a result of the economy but should rebound nicely when the economy recovers are:

GE, General Electric:
The GE stock has consistently been getting hammered for the better part of the last six months, mostly as a result of the market (in my opinion) and the decline in stock price is likely to continue for a little while longer.

Doubts about the company's ability to reach its earnings targets follow reports of GE subsidiary companies doing business with Iran and worries about the health of GE Capital, GE's Loan and Securities division that got hit by the recent credit crunch.

GE is also the parent company of NBC, the third-lowest rated of the big four TV networks, which will take a financial hit during this time of slumping television advertising revenue. Another factor that the GE NBC division faces is that MSNBC, the network's cable news channel, is attrocious both in content and viewership ratings.

For the above reasons, many analysts are slamming GE right now. They also point to the fact that much of GE's revenue for the fourth quarter will actually be a tax credit vice actual income. As a result of these analyst beatings, the GE stock continues to decline.

In VFC's opinion, all of the above indicates that it is time to buy GE, because now we will be able to buy at a discount, before the stock market begins it's recovery.

Stock analysts, for the most part, are self-serving predators that rarely give the small investor the proper indications of when to buy and sell. They'll tell you to sell now because the stock isn't looking to good, but by the time they tell you to buy again, you'll have missed a five or ten dollar jump in price. I look back a few years when all the analysts were telling us to buy Sprint from the high teens all the way down to about four bucks. When the stock hit four, they told us to sell. Make sense to you? The analysts want you to sell your shares of GE now so that their respective firms can buy them from you at a discounted price.

Don't get me wrong, there is some bad news coming from GE right now. We're in a serious recession, so there is no doubt that GE (and just about every company out there) is going to take a serious financial hit during these recession times, probably until 3Q 2009. On the other hand, GE is an American Icon that continuously boasts quarterly profits of at least $4 billion, and the company is far from going under.

The Government and Security contracts continue to roll in, GE continues to set the standard for innovative new technology and NBC will rebound, if for no other reason than that network can't get much worse.

I would not be surprised if GE actually reaches the single digits in the not-so-far-off future, at which time I will call it a screaming buy. For now, I'll continue to average down.

Once the economy and the market begin to rebound, GE should be a recipient of a good run.

Addtionally, Warren Buffet put billions into the GE stock towards the end of last year. I don't argue with that guy.

For those that are buying now, I'd call these discounted prices.
Sirius Satellite Radio Inc.

JWN, Nordstrom:
Luxury retailers are among the worst hit during economic recessions, but Nordstrom is one that will survive. The copany has taken measures to cut costs, holds a nice cash position and has a credit options if the recession drags on for an extended period of time. Nordstrom also has a wealthy clientele base that can afford to continue shopping at their stores, even in these tough times.

Currently the stock is trading near ten dollars, about a quarter of it's recent high.

When the economy begins to rebound, I expect that JWN will do the same and those that bought in at these low levels should reap the rewards of patience.

Bliss World, LLC

A small biotech with a possible huge future:

CVM, Cel-Sci:
Cel-Sci is developing a potentially breakthrough immunotherapy treatment for head and neck cancer called Multikine. Multikine, labelled as a potential billion dollar blockbuster by MedAd News, proved to be safe and tolerable in Phase II trials and also proved to extend the life of head and neck cancer patients by 33% (at a median of up to 3 1/2 years after surgery).

The company has constructed a recently completed Baltimore manufacturing facility where the production of Multikine will take place for the upcoming Phase III trial and, upon approval, commercial market distribution.

The stock dropped by 20% today after a terrible 2008 financial report making the risk-reward potential of CVM even more attractive. The poor 2008 numbers can be attributed to costs relating to the building of the manufacturing facility, Research & Development and some compensation for management.

As reported by the CEO, Geert Kersten, cash burn should decrease in the coming year due to the completion of the manufacturing facility. The company is also looking for additional partnerships in order to raise the funds necessary to carry on with the Phase III trials.

Cel-Sci already has two licensing agreements in place with Teva Pharmaceuticals.

CVM, as are all small biotechs, is a risky play, but with the stock trading for three dimes, the risk-reward is undeniable.

If Multikine is a success, this stock could send investors into an early retirement, but D-Day for CVM is still years away.

I've been accumulating shares for over a year now, taking advantage of all dips in price.

Follow the links below to read more posts regarding CVM.

CVM, VFC's Long Term Cancer Pick
CVM Update
CVM, A Stock Market Crash Pick
CVM and the Baltimore Facility
CVM and TEVA

AmericaRx.com

Novadel, NVD
VFC's Bear Market Stock Picks Part I
VFC's Bear Market Picks Part II
VFC's Bear Market Picks Part III
VFC's Bear Market Non Picks Part
VFC's Stock Updates
VFC's Bear Market Picks Part IV; CRYP, CSUH.OB
VFC's Biotech Picks
VFC's Quarterly Updates
INSM Update, IPLEX Back In Action




Monday, January 12, 2009

STOCK UPDATE: Celsius (CSUH.OB) Catches on With Katie Holmes

VFC's 2009 Stock Picks
Comments from Celsius CEO Steve Haley
Comments from Celsius CEO Steve Haley, Part I

The Celsius brand may finally be hitting the mainstream as Actress Katie Holmes was recently spotted with a bottle of the calorie burning beverage.

As I described two days ago, last year, the company launched two non-carbonated Green Tea flavors of the drink in addition to the five carbonated flavors. New products are also in the works.

On the advertising front, targeted radio ads started airing late last year and television ads are currently in production. It has long been my opinion, and the opinion of many others, that all this product needed was a successful advertising campaign to get the product awareness rolling. However, having an A-list celebrity such as Katie Holmes spotted with the drink is just as good as any advertising campaign, and it was only a matter of time before we got a 'celbrity with Celsius' photo op.



Katie Holmes drinking Celsius was big enough to be reported in England's Daily Mail, and if they hit the UK tabloids, you can be assured that these photos will hit the US gossip magazines as well, such as US weekly or the OK!. A small event such as this one can give Celsius some big, much needed exposure.

With the financing issue settled, distribution ramping up and now this celebrity sighting increasing consumer awareness, CSUH.OB could be in for a big 2009.

VFC just may add a few more shares on any dips back to under five cents.
ShareBuilder - Welcome page Zecco Holdings

Sunday, January 11, 2009

VFC's 2009 Stock Picks, Part II- Dendreon(DNDN)

DNDN, Dendreon:

Interim Results for Provenge

A new year is upon us and the Provenge Story continues.

Provenge, A Brief Recap:
Provenge (sipuleucel-T) is Dendreon's prostate cancer immunotherapy treatment that is currently being tested for effectiveness in a clinical Phase III trial called IMPACT.

In early 2007, Dendreon attempted to gain approval for Provenge with the US FDA and after an FDA Advisory Panel recommended approval, the outlook was promising. The Advisory Panel voted 17-0 that Provenge was safe and 13-4 that it showed efficacy. As a result of the positive recommendation, the DNDN stock skyrocketed from the four dollar range to the mid-twenty dollar range. The quick and unexpected rise in price of the DNDN stock was great for longs (such as VFC who was loaded with call options), but caught many short sellers by surprise and reportedly caused many hedge funds and financial institutions to lose big money.

About five weeks later the FDA issued an approvable letter for Provenge sending the stock south (great for those short on the stock and terrible for those longs that did not sell at the top; not to mention that it was a disappointing outcome, to say the least, for tens of thousands of prostate cancer patients who had their sights set on this novel, new treatment).

Following the FDA's decision to deny the market of Provenge, conflicts of interest surfaced regarding two Doctors that served on the advisory committee. These two Doctors were adamantly opposed to the approval of Provenge and they seemingly played a significant role in keeping it from reaching market. One of the two Doctors, Howard Scher, had huge connections with Novacea, who at the time was working on a competing treatment to Provenge. A laundry list of additional conflicts of interest surfaced, most of which were not declared when he was appointed to the panel.

Lawsuits were filed as patients and investors alike lobbied heavily to get the FDA to at least conditionally approve the treatment immediately. The FDA's only concession was to conditionally approve Provenge if midterm results (released late last year) demonstrated that Provenge would meet the trial endpoints.

The midterm results, although encouraging, did not overwhelming declare Provenge a success, so we continue to wait for the final results which are due later this year.


Provenge is the biggest name of the new breed of immunotherapies that may alter the way in which we treat cancer. It is unfortunate that the Provenge story has become so politically (and monetarily) charged, but nothing less could be expected in today's society where individual profit trumps ethics (see: Madoff, Bernie).

Oncophage, a kidney cancer treatment made by Antigenics(AGEN), became the world's first approved cancer immunotherapy treatment when it was approved by Russian medical officials last April. Provenge, it would seem, has the best chance at becoming the first to be approved in the United States.

I am still accumulating DNDN while it is trading in the four to five dollar range. If Provenge does meet survivability endpoints, then this stock will skyrocket on speculation of approval. If the trial fails, DNDN will be in the toilet.

Indications are that Provenge works, but the question is does it work enough to convince those at the FDA that prostate cancer patients will be better off receiving Provenge than the chemotherapy treatment of Taxotere that brings viscous side effects along with treatment.

The answer to that question will be determined later this year.

Dendreon is also conducting two additional Provenge Phase II trials and also has breast cancer treatment Neuvenge (Lapuleucel-T) undergoing clinical trials.

UPDATE: According to the Dendreon website, Neuvenge trials are currently on hold as the company directs all efforts to the advancement of Provenge.

Quote taken directly from the Dendreon website:
We are evaluating future development plans for lapuleucel-T.


The big news on the horizon for Dendreon (DNDN), is the final results of the IMPACT trial, regardless of any additional testing. The anticipation of these results can start to wreak havoc on the volatility of the stock as the release date approaches. It is still not too late to get in now, whether it be a long or short position, but I, for one, am hoping that this potentially groundbreaking therapy makes it to market.

'Cancer vaccines, Where are they now?'- From Sept '08

ShareBuilder - Welcome page NutriSystem Free Week of Food with NutriSystem breakfastVitamin World

Friday, January 9, 2009

VFC's 2009 Stock Picks, Part I

VFC's 2009 Stock Picks, Part I

The Big Boys:

GILD, Gilead Sciences- I first bought into this company in early 2007 when I purchased some shares for the long term and then some call options for the short term. I sold the call options for a nice profit just before the FDA approval of Ambrisentan (Letairis) and I've held onto the shares since, only adding occasionally. I have once again begun to accumulate shares of GILD, and I'll continue to accumulate long term shares while they are trading for roughly $50.00, as they are now.

Gilead Sciences has become a staple in the treatment of HIV and should maintain a foothold in that arena for years to come. Additionally, the company is looking to expand outside the boundaries of HIV treatment and is developing drugs that will treat the flu, hypertension and hepatitis.

Gilead is also sitting on about three billion dollars in cash, giving the company great flexibility when it comes to acquisitions, mergers and other transactions. Another possibility is a buyout of Gilead by a big Pharma, such as Pfizer (PFE).

I like the growth potential of the company, and I believe we've only seen the beginning of Gilead Sciences. GILD should be a great growth story in the next few years, and VFC will be accumulating until the $60 mark.
ShareBuilder- Welcome page

GOOG, Google:
A few years from now, in my opinion, we'll be looking back at GOOG and realizing what a steal it was while trading at the $300 level. The stock is down by more than 50% from its high, mostly as a result of the economic downturn and a couple of quarters with less than expected growth.

Although the company is pushing into other areas (browsers, phone applications, etc.), the majority of their income (now and in the foreseeable future) generates from Internet advertising. While companies are slashing advertising budgets, I believe that Internet advertising will continue to grow and the money for Google will always be there. In short, it will be television advertising that takes the biggest hit, but Internet advertising will continue to grow.

The major television networks will suffer as the advertising money transfers from TV to the Internet, not Google. With TiVo and DVRs now commonplace, the networks cannot guarantee that their ads are being viewed. With Google AdSense, the advertiser only has to pay when they know that someone is looking at their ad (measured by an ad click). Advertising money much better spent in the view of the advertiser.

Aside from the advertising revenue, of which Google dominates the market share, Google can potentially steal market share in other arenas with it's new web browser and other developing technology. The company is pouring money into research for alternative energy and possible health care applications- both potential big money generators.

GOOG has come back to earth after flying high after the $80 IPO, but Google's time is not gone, it may be just beginning. I believe we're buying at a near 50% discount right now.

You can count on VFC accumulating GOOG for the real long term. I still think Google could eventually take over the world if they wanted to. Remember Skynet from Terminator II? That's Google.
Apple iTunes

MSFT, Microsoft:
I'm always buying Microsoft when it is trading in the low twenties and right now it is on sale for right around twenty bucks.

Microsoft is still lagging in the search engine business and the Microsoft Zune is no iPod, but Windows will continue to carry this company until its next big thing comes out.

A takeover of Yahoo!(YHOO) may be revisited when that company appoints a new CEO after two failed attempts to buy the company last year. YHOO is currently trading at less than half of what it was during the Microsoft takeover talks.

This company is constantly sitting on gobs of cash and pays out a decent dividend.

For twenty bucks, I'm buying and I expect a push to over thirty again once the economy turn around.
Microsoft Store

The little engine that could:

CSUH.OB, Celsius Holdings:
2009 brings in a new year for this little company, and the new year brings a new start.

Steve Haley and the rest of the Celsius board got the ball rolling in 2008 by introducing radio advertisements, two new Green Tea products and by bringing Carl DeSantis on board. These events have 2009 set up to be a year of growth and potential for the small company.

For those new to the Celsius product and/or stock, Celsius is the world's first calorie burning beverage. Four clinical studies have shown that drinking one 12-oz serving of Celsius burns around 100 calories over a three hour period. The carbonated beverage comes in five flavors and the non-carbonated Green Tea comes in two flavors.

Recently, a Carl DeSantis company allowed Celsius Holdings to consolidate their debt under new and more favorable terms to the company. Included in the refinancing is a line of credit which the company can tap as needed. That took care of the financing issue that had investors worried.

In addition to the financing news, we've learned that new calorie burning products are under development and should be released later this year. The more variety of products offered by the company, the easier it will be to gain a foothold in the supplement, energy drink and weight loss markets. At that point, we could be assured that Carl DeSantis will use his influence and contacts to make the Celsius brand known.

Celsius also signed many new distribution agreements last year and now is the time that we should start seeing results from the new distribution.

Another huge factor this year will be the introduction of television ads. These ads will in specific, targeted markets and should do wonders to increase sales in the targeted area.

The slow economy could hurt the company in the short term, as people are holding onto their money and may not splurge for a $2 energy drink. On the other hand, it is the new year and people will flock to the gym in a quest to lose weight. A calorie burning beverage like Celsius may do pretty good at this time of the year.

After taking a beating last year, and giving investors the opportunity to buy in on the low, CSUH.OB has already started to rebound. The stock ended the week trading at about 60% more than the it was at the beginning of the year (closed at seven cents).

CSUH.OB is a risky stock, but if the brand catches on makes a dent in the food and beverage industry, huge rewards could be had for those that bought in now.

I'm loaded to a point where I am comfortable with this stock, but if it dips to the three cent level I'll probably buy more. For now I'm holding what I've got.

Comments from Celsius CEO Steve Haley



A few biotech companies that have approved drugs and are trading at bargain prices (in my opinion) due to the economic downturn:

EPCT, Epicept:
Epicept's lead drug, Ceplene, was approved earlier this year for marketing and distribution in Europe. The company has also applied for approval in Canada.
News of a partnership to distribute Ceplene may come in early 2009. Once that news comes and as Ceplene comes closer to bringing in revenue, EPCT should start reflecting those positive events.

Additionally, Epicept has multiple other drugs in the pipeline to treat cancer and pain.

As long as EPCT trades below a buck, I'm accumulating.

AGEN, Antigenics:
Antigenics was the first to have a cancer immunotherapy approved in the world when Oncophage was approved in Russia last April.

AGEN should begin to climb as the time comes closer for revenue from Oncophage. I don't expect huge things from AGEN, but a trading range of $2-$4 dollars later this year is entirely possible.

Once Oncophage is used for treatment in Russia, that data, if positive, may be used to get the drug approved elsewhere.

I'm still accumulating AGEN as long as it trades for under a buck.

NVD, Novadel:
Another company with an approved drug (2, actually) that is on sale in this deflated market. This stock is highly manipulated, in my opinion, but once the economy is turned around and revenue comes in for the two approved drugs, then NVD could easily become a ten bagger from its current level.

The stock already made huge gains at the end of last year, so expect some volatility at low levels as the big boys reposition themselves for another run.

In the meantime, I'm still accumulating in the thirty to forty cent range.
236x60 Advanced New Year 2

Novadel, NVD
VFC's Bear Market Stock Picks Part I
VFC's Bear Market Picks Part II
VFC's Bear Market Picks Part III
VFC's Bear Market Non Picks Part
VFC's Stock Updates
VFC's Bear Market Picks Part IV; CRYP, CSUH.OB
VFC's Biotech Picks
VFC's Quarterly Updates
INSM Update, IPLEX Back In Action

Follow by Email